PT  - JOURNAL ARTICLE
AU  - Laure Gossec
AU  - Joanna Kedra
AU  - Hervé Servy
AU  - Aridaman Pandit
AU  - Simon Stones
AU  - Francis Berenbaum
AU  - Axel Finckh
AU  - Xenofon Baraliakos
AU  - Tanja A Stamm
AU  - David Gomez-Cabrero
AU  - Christian Pristipino
AU  - Remy Choquet
AU  - Gerd R Burmester
AU  - Timothy R D J Radstake
TI  - EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases
AID  - 10.1136/annrheumdis-2019-215694
DP  - 2019 Jul 08
TA  - Annals of the Rheumatic Diseases
PG  - annrheumdis-2019-215694
4099  - http://ard.bmj.com/content/early/2019/07/07/annrheumdis-2019-215694.short
4100  - http://ard.bmj.com/content/early/2019/07/07/annrheumdis-2019-215694.full
AB  - Background Tremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs).Methods A multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated.Results Three overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice.Conclusion These EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.